Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.
Di Blasio S, van Wigcheren GF, Becker A, van Duffelen A, Gorris M, Verrijp K, Stefanini I, Bakker GJ, Bloemendal M, Halilovic A, Vasaturo A, Bakdash G, Hato SV, de Wilt JHW, Schalkwijk J, de Vries IJM, Textor JC, van den Bogaard EH, Tazzari M, Figdor CG. Di Blasio S, et al. Among authors: tazzari m. Nat Commun. 2020 Jun 2;11(1):2749. doi: 10.1038/s41467-020-16583-0. Nat Commun. 2020. PMID: 32488012 Free PMC article.
Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G, Vergani B, Piccinini F, Carbonaro A, Leone BE, Foschi G, Ancarani V, Framarini M, Guidoboni M. Bulgarelli J, et al. Among authors: tazzari m. Front Immunol. 2019 Oct 9;10:2353. doi: 10.3389/fimmu.2019.02353. eCollection 2019. Front Immunol. 2019. PMID: 31649669 Free PMC article. Clinical Trial.
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C. Camisaschi C, et al. Among authors: tazzari m. Cancer Immunol Immunother. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16. Cancer Immunol Immunother. 2013. PMID: 23589107 Free PMC article. Clinical Trial.
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V, Di Guardo L, Lalli L, Giardiello D, Cova A, Squarcina P, Frati P, Di Giacomo AM, Pilla L, Tazzari M, Camisaschi C, Arienti F, Castelli C, Rodolfo M, Beretta V, Di Nicola M, Maio M, Del Vecchio M, de Braud F, Mariani L, Rivoltini L. Huber V, et al. Among authors: tazzari m. J Immunother Cancer. 2021 Feb;9(2):e001167. doi: 10.1136/jitc-2020-001167. J Immunother Cancer. 2021. PMID: 33589521 Free PMC article.
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival.
Tumedei MM, Piccinini F, Azzali I, Pirini F, Bravaccini S, De Matteis S, Agostinelli C, Castellani G, Zanoni M, Cortesi M, Vergani B, Leone BE, Righi S, Gazzola A, Casadei B, Gentilini D, Calzari L, Limarzi F, Sabattini E, Pession A, Tazzari M, Bertuzzi C. Tumedei MM, et al. Among authors: tazzari m. Int J Mol Sci. 2023 Jun 8;24(12):9909. doi: 10.3390/ijms24129909. Int J Mol Sci. 2023. PMID: 37373066 Free PMC article.
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato AM, Pancisi E, Foca F, Dall'Agata M, Bondi I, Amadori E, Cortesi P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini D, Maimone G, Arpa D, Tosatto L. Ridolfi L, et al. Among authors: tazzari m. Front Immunol. 2024 Aug 13;15:1404861. doi: 10.3389/fimmu.2024.1404861. eCollection 2024. Front Immunol. 2024. PMID: 39192978 Free PMC article. Clinical Trial.
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.
Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C. Tazzari M, et al. J Immunol Res. 2018 Oct 29;2018:5804230. doi: 10.1155/2018/5804230. eCollection 2018. J Immunol Res. 2018. PMID: 30510965 Free PMC article.
32 results